目的：探讨温经散寒通络汤联合针灸治疗类风湿性关节炎寒湿痹的临床疗效。方法：选择类风湿性关节炎寒湿痹患者88 例，随机分为对照组和治疗组，对照组44 例，给予口服双氯芬酸钠、柳氮磺胺吡啶、甲氨蝶呤；治疗组44 例，在西治疗基础上，加服温经散寒通络汤和针灸治疗。每组均治疗猿个月，观察临床症状、体征和实验室指标改善情况。结果：两组在治疗前后比较，在临床症状、体征和实验室指标上均有较大改善（孕＜0.05）；治疗组在改善休息痛、肿胀个数、肿胀指数、压痛个数、压痛指数、晨僵时间、肝肾功与对照组相比无统计学差异；与对照组比较，治疗组在改善关节功能障碍、双手握力及降低红细胞沉降率（ESR）、悦反应蛋白（CRP）、类风湿因子（RF）等有更明显的优势（孕＜0.05）。结论：与单纯西药治疗相比，温经散寒通络汤联合针灸，结合西药治疗对类风湿性关节炎关节功能的改善、病情活动的控制有一定的优势。

This study was aimed to explore clinical effect on treatment of rheumatoid arthritis (RA) of cold-dampness syndrome by the combination of Wen-Jing San-Han Tong-Luo (WJSHTL) decoction and acupuncture. A total of 88 RA patients were selected and randomly divided into the control group and the treatment group. All 44 cases in the control group were orally administrated with diclofenac sodium, sulphasalazine (SASP) and methotrexate (MTX). All 44 cases in the treatment group were treated with the combination of WJSHTL decoction and acupuncture on the basis of western medication the same as the control group. Each group was treated for three months. Improvements of clinical symptoms, body signs and laboratory indexes were observed. The results showed that clinical symptoms, body signs and laboratory indexes were greatly improved in the comparison before and after treatment in both groups with statistical significance (P < 0.05). Compared to the control group, the treatment group had no statistical significance in the improvement of rest pain, swelling numbers and index, tenderness numbers and index, morning stiffness time,liver and kidney function. Compared with the control group, the treatment group had more obvious advantages in the improvement of joint function, hand grip strength, erythrocyte sedimentation rate (ESR) decreasing, C-reactive protein (CRP) and rheumatoid factor (P < 0.05). It was concluded that compared with single western medication, the combination of WJSHTL decoction and acupuncture with western medication had certain advantages in the improvement of joint function of RA and management of patient's disease condition.

重庆市卫生局中医药科技计划项目（2010-2-66）：调控乳腺癌细胞DNA 甲基化转移酶活性的中药单体筛选，负责人：周萍。